TABLE 6.
M6A‐miRNAs based targeting therapy
| miRNA | Cancer type | M6A regulators | Mechanism | Ref |
|---|---|---|---|---|
| miR‐92b‐3p | Gallbladder cancer | METTL3 | DAC inhibit METTL3/miR‐92b‐3p related cancer progression | 54 |
| miR‐483‐3p | Breast cancer | METTL3 | Metformin exerts anti‐growth effect via METTL3/miR‐483‐3p | 48 |
| miR‐17‐92 cluster | Gastric cancer | METTL3 | Overexpressed METTL3 accelerates everolimus sensitivity by stimulating mTOR pathway | 81 |
| miR‐29a/b, miR‐222/1266/1268a/671‐3p | Breast cancer | HNPNPA2B1 | HNPNPA2B1 inhibitor might alleviate endocrine resistance | 74 |
| miR‐221‐3p | Breast cancer | METTL3 | Excessive METTL3 drive Adriamycin resistance | 82 |